Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Samsung entangled in legal risks amid calls for drastic reform

    Samsung entangled in legal risks amid calls for drastic reform
  2. 2

    Heavy snow alerts issued in greater Seoul area, Gangwon Province; over 20 cm of snow seen in Seoul

    Heavy snow alerts issued in greater Seoul area, Gangwon Province; over 20 cm of snow seen in Seoul
  3. 3

    Seoul blanketed by heaviest Nov. snow, with more expected

    Seoul blanketed by heaviest Nov. snow, with more expected
  4. 4

    [Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'

    [Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'
  5. 5

    Samsung shakes up management, commits to reviving chip business

    Samsung shakes up management, commits to reviving chip business
  1. 6

    Seoul snowfall now third heaviest on record

    Seoul snowfall now third heaviest on record
  2. 7

    K-pop fandoms wield growing influence over industry decisions

    K-pop fandoms wield growing influence over industry decisions
  3. 8

    Heavy snow of up to 40 cm blankets Seoul for 2nd day

    Heavy snow of up to 40 cm blankets Seoul for 2nd day
  4. 9

    Seoul's first snowfall could hit hard, warns weather agency

    Seoul's first snowfall could hit hard, warns weather agency
  5. 10

    How $70 funeral wreaths became symbol of protest in S. Korea

    How $70 funeral wreaths became symbol of protest in S. Korea
소아쌤

Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®

By

Published : Aug. 3, 2021 - 22:20

    • Link copied

SEOUL, South Korea, Aug. 3, 2021 /PRNewswire/ -- Yuyu Pharma, a pharmaceutical company based in Korea, and Novartis Korea announced today that the companies have entered into an agreement in which Yuyu will have exclusive distribution rights for the following prescription medicines in Korea: Lamisil® for the treatment of athlete's foot; Lescol® XL for the treatment of dyslipidemia; and the Tegretol® for the treatment of epilepsy. This agreement will be in effect beginning August 1st, 2021.

Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®
Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®

"With their marketing capabilities and a strong compliance system, we believe Yuyu Pharma is the ideal partner. This partnership will be mutually beneficial to both companies, and to patients who need access to these well-established medication," stated Kyung-ryung Song, Head of Business Development & Licensing at Novartis Korea.

Wonsang Yu, CEO of Yuyu Pharma said, "We at Yuyu emphasize the importance of good business practices and compliance. And we believe that Novartis Korea selected Yuyu as its partner for such values. We thank Novartis Korea for entrusting us with these important products and will continue to meet the needs our customers and patients."

Lamisil® tablet is a single ingredient prescription medicine containing Terbinafine hydrochloride used for the treatment of ringworm of the foot, ringworm of the body, and fungal infections of the fingernail and toenail.

Lescol® XL prolonged-release tablet is a single ingredient prescription medicine containing Fluvastatin sodium. Lescol® XL is effective in delaying the progression of coronary atherosclerosis in patients suffering from primary hypercholesterolemia and coronary artery disease, reducing the risk of recurrence of heart accidents after coronary intubation as well as reducing hyperlipidemia.

Tegretol® is a single ingredient prescription medicine containing carbamazepine used to treat epilepsy, trigeminal neuralgia, manic depressive disorder, and schizophrenia. The Tegretol® series consists of Tegretol® slow-release film coated tablets, Tegretol® tablets, and Tegretol® syrup.

Media Enquiries:

Sean Yoon
hjyoon@yuyu.co.kr

 

More from Headlines